Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $30.7 million.

  • Cytokinetics' Share-based Compensation rose 21.06% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $108.0 million, marking a year-over-year increase of 18.61%. This contributed to the annual value of $97.8 million for FY2024, which is 35.77% up from last year.
  • Per Cytokinetics' latest filing, its Share-based Compensation stood at $30.7 million for Q3 2025, which was up 11.48% from $27.5 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Share-based Compensation ranged from a high of $30.7 million in Q3 2025 and a low of $5.3 million during Q1 2021.
  • For the 3-year period, Cytokinetics' Share-based Compensation averaged around $22.9 million, with its median value being $23.5 million (2025).
  • Data for Cytokinetics' Share-based Compensation shows a peak YoY soared of 100.46% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Cytokinetics' Share-based Compensation stood at $6.7 million in 2021, then surged by 100.46% to $13.5 million in 2022, then soared by 44.85% to $19.5 million in 2023, then skyrocketed by 34.71% to $26.2 million in 2024, then grew by 21.06% to $30.7 million in 2025.
  • Its last three reported values are $30.7 million in Q3 2025, $27.5 million for Q2 2025, and $23.5 million during Q1 2025.